Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)

Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Placebo;   Biological: Mepolizumab Sponsors:   GlaxoSmithKline;   PPD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials